Table 3 HPV persistence and clearance rate at 12-month follow up without treatment stratified by HPV type.
HPV genotypes | Frequency | Baseline | 12 months Persistent and clearance rate without treatment | |||
|---|---|---|---|---|---|---|
Persistent rate | Clearance rate | 95% CI | P-value | |||
High and probable high risk | 89 | 41 | 46.34%(19/41) | 53.7%(22/41) | 0.377–0.696 | < 0.001 |
Type-16 | 40 | 13 | 76.92%(10/13) | 23.08%(3/13) | -0.03-0.49 | 0.082 |
Type 16 alone | 24 | 8 | 62.5%(5/8) | 37.5%(3/8) | -0.06-0.81 | 0.08 |
Type-18 | 16 | 7 | 57.14%(4/7) | 42.9%(3/7) | -0.07-0.92 | 0.078 |
Type-35 | 12 | 6 | 33.33%(2/6) | 66.67%(4/6) | 0.13–1.21 | 0.025 |
Type-52 | 12 | 4 | 75%(3/4) | 25%(1/4) | -0.55-1.05 | 0.391 |
Type-58 | 18 | 8 | 50%(4/8) | 50%(4/8) | 0.05–0.95 | 0.033 |
Other high risks (HPV-31/33/39/45/51/56/59/66/68 | 24 | 15 | 40%(6/15) | 60%(9/15) | 0.32–0.88 | < 0.001 |
Possible and low risk | 31 | 21 | 47.62%(10/21) | 52.4%(11/21) | 0.29–0.76 | < 0.001 |
Type-53 | 16 | 9 | 44.44%(4/9) | 55.6%(5/9) | 0.15–0.96 | 0.013 |
Type-70 | 8 | 6 | 50%(3/6) | 50%(3/6) | -0.08-1.08 | 0.076 |
Other possible and low risks (HPV-6/11/26/40/42/44/54/61/73/82) | 16 | 13 | 53.85%(7/13) | 46.15%(6/13) | 0.15–0.78 | < 0.001 |
Single | 58 | 28 | 32.1%(9/28) | 67.9%(19/28) | 0.49–0.86 | < 0.01 |
Multiple | 31 | 13 | 76.9%(10/13) | 23.1%(3/13) | -0.03-0.49 | 0.082 |
